{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit could not be calculated from the data due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"0.6","upperLimit":"NA","value":"1.0"},{"comment":"The upper limit could not be calculated from the data due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"9.3","upperLimit":"NA","value":"22.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"Tumor assessment was performed using RANO for participants with HGG and RECIST v1.1 for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with High Grade Glioma.","id":"OG000","title":"High Grade Glioma"},{"description":"Participants with Low Grade Glioma.","id":"OG001","title":"Low Grade Glioma"}],"paramType":"MEDIAN","populationDescription":"The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. For phase II, only one tumor type cohort was opened (LGG). As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.","reportingStatus":"POSTED","timeFrame":"From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)","title":"PFS as Determined by the Investigator Using RANO Criteria for Participants With HGG (Phase I) and RECIST v1.1 for Partcipants With LGG (Phase I and II)","type":"PRIMARY","unitOfMeasure":"Months"}